Action ACHFF ARCH BIOPARTNERS INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Arch Biopartners Inc.

Actions

ACHFF

CA03938C1041

Marché Fermé - OTC Markets
Autres places de cotation
 21:57:08 24/04/2024 		Varia. 5j. Varia. 1 janv.
1,55 USD -4,32 % Graphique intraday de Arch Biopartners Inc. -9,88 % +38,83 %
16/04 Arch Biopartners Inc. Michael's Hospital se joint à l'essai de phase II du peptide LSALT ciblant les lésions rénales aiguës associées à la chirurgie cardiaque CI
03/04 Arch Biopartners annonce que le University Health Network se joint à l'essai de phase II du peptide LSALT MT

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Arch Biopartners Inc. - St. Michael's Hospital Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
Arch Biopartners Says St. Michael's Hospital Joins Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-AKI
Arch Biopartners Brief: Says St. Michael's Hospital Joins Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
St. Michael’s Hospital Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
Arch Biopartners Inc. Announces St. Michael's Hospital Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
Arch Biopartners Says University Health Network Joining Phase II Trial of LSALT Peptide
Anesthesia Clinical Trials Unit Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery-Associated-Acute Kidney Injury
UHN Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
Arch Biopartners Adds Three Clinical Sites in Turkey For Phase II Trial for LSALT Peptide
Arch Biopartners Adds Three New Clinical Sites into the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
Arch Biopartners Adds Three New Clinical Sites into the Phase Ii Trial for Lsalt Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
Arch Biopartners Clinical Team Publishes Data from Phase II Trial for LSALT Peptide Targeting Organ Inflammation
Arch Biopartners Clinical Team Publishes Data from Phase II Trial for LSALT Peptide Targeting Organ Inflammation in Hospitalized Patients Infected with SARS-CoV-2
Arch Biopartners Clinical Team Publishes Data from Phase II Trial for Lsalt Peptide Targeting Organ Inflammation in Hospitalized Patients Infected with Sars-Cov-2
Arch Biopartners Says University of Calgary Joins Phase II Trial of LSALT Peptide Targeting Cardiac Surgery-Associated AKI
University of Calgary Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
University of Calgary Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
Arch Biopartners Announces Dosing Of Patient In Phase II Trial For LSALT Peptide
Arch Biopartners Announces Dosing of First Patient in Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
Arch Biopartners Inc. Announces Dosing of First Patient in Phase II Trial for LSALT Peptide Targeting Cardiac Surgery-Associated-Acute Kidney Injury
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action ACHFF
  4. Actualités Arch Biopartners Inc.
  5. Autres langues